Program
roxadustat
Also written as “Roxadustat”, “FG-4592” and “ASP1517”.
Its studies are mostly in Anemia · Renal Insufficiency, Chronic · Kidney Failure, Chronic · Myelodysplastic Syndromes · Renal Insufficiency, led by 3 companies.
Drug pageRoxadustat: every studyAll 63 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Astellas Pharmaits history only | 221 open or running | phase 3since Jun 25, 2013 | Sep 15, 2009 | Oct 30, 2027phase 3 · NCT05970172 |
| Kyntra Bio | 221 open or running | phase 4since Aug 8, 2019 | Sep 25, 2008 | Sep 2030phase 3 · NCT07722988 |
| AstraZenecaits history only | 30 open or running | phase 4since Dec 3, 2020 | Jun 24, 2014 | none ahead |
Also a collaborator on its studies: Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Kyntra Bio only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 7 studies since Sep 25, 2008.
- Jun 8, 2012Phase 2 study in Renal Insufficiency, ChronicNCT01630889 · 15 enrolled · United States, Puerto Rico
- Dec 11, 2012Phase 3 study in AnemiaNCT01750190 · 922 enrolled · United States, Argentina, Australia and more
- Jan 6, 2014Phase 3 study in AnemiaNCT02052310 · 1,043 enrolled · United States, Argentina, Bulgaria and more
- Oct 22, 2014Phase 3 study in AnemiaNCT02273726 · 741 enrolled · United States, Puerto Rico
- Dec 31, 20152 phase 3 studies in AnemiaNCT02652819, NCT02652806
- Aug 22, 2017Phase 3 study in AnemiaNCT03263091 · 184 enrolled · United States, Australia, Belgium and more
- Oct 2, 2017Phase 3 study in AnemiaNCT03303066 · 43 enrolled · China
- Aug 8, 2019Phase 4 study in AnemiaNCT04059913 · 318 enrolled · China
- Aug 30, 2019Phase 2 study in AnemiaNCT04076943 · 92 enrolled · United States
- May 27, 2020Phase 3 study in Anemia Associated With End Stage Renal Disease (ESRD)NCT04410198 · 203 enrolled · United States
- Jul 21, 2020Phase 3 study in Anemia Associated With End Stage Renal DiseaseNCT04484857 · 283 enrolled · United States
- Nov 3, 2020Phase 3 study in AnemiaNCT04621331 · United States
- Mar 19, 2022Phase 3 study in Chemotherapy Induced AnemiaNCT05301517 · 159 enrolled · China
- Jul 20, 2026Phase 3 study in Myelodysplastic SyndromesNCT07722988 · 201 planned
Ahead
- Sep 2030Primary completion: phase 3 study in Myelodysplastic SyndromesNCT07722988
TargetBeta
“Hypoxia-inducible factor prolyl hydroxylase inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| daprodustatrule | GlaxoSmithKline | phase 3 | 33 |
Studies
All 22 Kyntra Bio leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07722988Myelodysplastic Syndromes | 3 | Not yet recruiting | Sep 2030 | 201 |
| NCT05301517Chemotherapy Induced Anemia · China | 3 | Completed | Apr 3, 2023 | 159 |
| NCT04621331Anemia · United States | 3 | Withdrawn | May 23, 2022 | 0 |
| NCT04484857Anemia Associated With End Stage Renal Disease · United States | 3 | Completed | Jul 9, 2021 | 283 |
| NCT04410198Anemia Associated With End Stage Renal Disease (ESRD) · United States | 3 | Completed | Jun 30, 2021 | 203 |
| NCT04076943Anemia · United States | 2 | Completed | Mar 26, 2021 | 92 |
| NCT04059913Anemia · China | 4 | Completed | Nov 19, 2021 | 318 |
| NCT03303066Anemia · China | 3 | Completed | Jan 11, 2023 | 43 |
| NCT03263091Anemia · United States, Australia, Belgium and more | 3 | Terminated | Mar 9, 2023 | 184 |
| NCT02652819Anemia · China | 3 | Completed | Jan 24, 2017 | 154 |
| NCT02652806Anemia · China | 3 | Completed | Jan 24, 2017 | 305 |
| NCT02273726Anemia · United States, Puerto Rico | 3 | Completed | Sep 19, 2018 | 741 |
| NCT02052310Anemia · United States, Argentina, Bulgaria and more | 3 | Completed | Sep 21, 2018 | 1,043 |
| NCT01750190Anemia · United States, Argentina, Australia and more | 3 | Completed | Sep 24, 2018 | 922 |
| NCT01630889Renal Insufficiency, Chronic · United States, Puerto Rico | 2 | Completed | Dec 12, 2019 | 15 |
| NCT01599507Anemia · China | 2 | Completed | Jan 2013 | 91 |
| NCT01596855Anemia · China | 2 | Completed | Jan 2013 | 96 |
| NCT01414075Anemia · United States, Hong Kong, Russian Federation and more | 2 | Completed | Jan 10, 2013 | 60 |
| NCT01376063Healthy Adult Subjects | 1 | Completed | May 2010 | 20 |
| NCT01244763Renal Insufficiency, Chronic · United States, Puerto Rico | 2 | Completed | Jun 13, 2012 | 145 |
| NCT01147666Kidney Failure, Chronic · United States | 2 | Completed | Oct 15, 2012 | 161 |
| NCT00761657Renal Insufficiency, Chronic · United States | 2 | Completed | Jun 21, 2010 | 117 |
How it is read
Names in the registry
- “Roxadustat”, 25 entries
- “FG-4592”, 9 entries
- “roxadustat”, 8 entries
- “ASP1517”, 5 entries
Conditions, from the studies’ own filings
- Anemia, 25 studies
- Renal Insufficiency, Chronic, 7 studies
- Kidney Failure, Chronic, 4 studies
- Myelodysplastic Syndromes, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.